Feature

Accelerating Structure-based Drug Design for Complex Membrane Proteins

Nuclera and leadXpro partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets

  • By

  • March 9, 2026

  • 3 min

Share

  • 1

    Nuclera partners with leadXpro for drug discovery.

  • 2

    Focus on membrane protein screening improvements.

  • 3

    AI and ML integrated into protein design.

  • 4

    Workflow aims to streamline structural insights.

  • 5

    Challenges in purifying membrane proteins addressed.

  • 6

    Technological integration enhances drug candidate progression.

Original Source(s)

Accelerating Structure-based Drug Design for Complex Membrane Proteins

Nuclera and leadXpro partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets

  • March 9, 2026

  • 3 min

Related Content

A Pharmacologic Off-Switch for Split CARs

Study describes a venetoclax-regulated off-switch CAR system with dose-dependent control of receptor assembly in vitro and in vivo

  • March 3, 2026

  • 2 min
Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer

New Collaboration to Automate Cell Therapy Manufacturing with Robotics

Focus on scaling cell therapy manufacturing using GMP-ready end-to-end robotic biomanufacturing technology

  • February 12, 2026

  • 2 min